House investigation says FDA approval process of Alzheimer's drug was 'rife with irregularities'
A congressional investigation found that the US Food and Drug Administration’s “atypical collaboration� to approve a high-priced Alzheimer’s drug was “rife with irregularities.�
As featured on
A congressional investigation found that the US Food and Drug Administration's "atypical col…